TIDMHEIQ
RNS Number : 4268X
HeiQ PLC
30 August 2022
30 August 2022
HeiQ Plc
("HeiQ" or "the Company")
Notice of H1 2022 Results and Presentation
HeiQ Plc (LSE: HEIQ), a Swiss IP innovator and established
global brand in materials and textile innovation which operates in
high-growth markets , is pleased to announce that its results for
the six months ended 30 June 2022 ("H1 2022") will be published on
Tuesday 13 September 2022.
H1 2022 Trading Update
HeiQ is pleased to report that the Company is expecting to
report revenue of over US$30m for H1 2022, an increase of more than
17% compared to the six months ended 30 June 2021 ("H1 2021")
(US$25.8m). This growth has been achieved despite the challenging
macro-economic environment, including the shutdown of key markets
in China for over three months during the six-month period. The
Company expects to report gross profit margins for H1 2022 of
46.7%, an improvement from the levels seen in the second half of
the 2021 financial year (43.7%). Whilst the increased cost of raw
materials placed pressure on margin during the period, pleasingly,
the trend of margin improvement is continuing into the second half
of this financial year ("H2 2022"), as the benefit of passed on
price increases materialise and raw material costs start to
stabilise.
HeiQ is pleased to report significant progress regarding the
development of its potential blockbuster technologies:
-- HeiQ successfully launched HeiQ AeoniQ, a high performance,
climate positive, cellulose yarn designed as a sustainable
substitute for the US$135 billion Polyester and Nylon market.
-- Received investment from HUGO BOSS which provides an implied
valuation of US$200 million for the platform.
-- All contractual milestones with HUGO BOSS have been met,
releasing US$9 million contractual payments and the pilot
commercialisation plant has successfully commenced.
-- Tangible progress has also been achieved for its other
potential blockbuster technologies, HeiQ GrapheneX, with the
validation of a solid state batteries prototype at double energy
capacity, and HeiQ Synbio recognised in a peer reviewed publication
by Europe's leading Hospital, Charité Berlin confirming the
potential to reduce Hospital Acquired Infections
HeiQ has demonstrated a resilient trading performance during H1
2022 and the Directors remain optimistic that the Company will
trade in-line with market guidance for the full financial year,
although, like all companies, the Company is not immune from the
impact of unforeseen global economic events and raw material
spikes.
Details of briefing for equity analysts
Carlo Centonze, CEO, and Xaver Hangartner, CFO will host a
briefing for analysts relating to its H1 2022 results for equity
analysts at 09:30 a.m. BST on Tuesday 13 September 2022 . Any
equity analysts wishing to attend or register should contact SEC
Newgate UK at HeiQ@secnewgate.co.uk where further details will be
provided.
Details of webinar for investors
The Company is also pleased to announce that Carlo Centonze and
Xaver Hangartner will provide a live presentation relating to its
H1 2022 results via the Investor Meet Company platform on Wednesday
14 September at 12:00 p.m. BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 09:00 a.m. the day before
the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet HeiQ Plc via:
https://www.investormeetcompany.com/heiq-plc/register-investor
Investors who have already registered and added to meet the
Company will be automatically invited.
For further information, please contact:
HeiQ Plc
Carlo Centonze (CEO) +41 56 250 68 50
Cenkos Securities plc (Joint Broker)
Stephen Keys / Callum Davidson +44 (0) 207 397 8900
---------------------
SEC Newgate (Media Enquiries) +44 (0) 20 3757 6882
Elisabeth Cowell / Axaule Shukanayeva / HeiQ@s ecnewgate
Molly Gretton .co.uk
---------------------
About HeiQ
HeiQ is focused on improving the lives of billions of people
world-wide by innovating the materials people use every day. HeiQ
has strong IP which is at the forefront of global technology in the
$10 billion antimicrobial fabrics market, $24 billion textile
chemicals market, the $50 billion probiotics market and the $150
billion man-made fibers market. It has also moved into the medical
device, healthcare and hygiene coatings markets, to help make
hospitals and healthcare environments more hygienic. HeiQ aims to
deliver growth for its shareholders through a combination of
increased sales of its core products and by entering additional
lucrative markets through disruptive innovations and M&A.
HeiQ has created some of the most effective, durable and
high-performance technologies in the market today, which cool,
warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has
developed over 200 technologies in partnership with 300 major
brands and it has a significant R&D pipeline containing over 50
projects. The Company has won multiple awards and gained a strong
reputation for the ESG & sustainable downstream effect of its
innovations. HeiQ is the only company to have won the Swiss
Technology award twice. It has also won the Swiss Environmental
award with an innovation that saves energy and water consumption
during the textile manufacturing process.
Led by an experienced leadership team, HeiQ researches new
solutions for partners, delivers scaled up manufacturing from its
sites across the world and helps partners market the product to end
consumers - aiming for lab to consumer in months.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPFMITMTMTBPT
(END) Dow Jones Newswires
August 30, 2022 02:00 ET (06:00 GMT)
Heiq (LSE:HEIQ)
Historical Stock Chart
From Nov 2024 to Dec 2024
Heiq (LSE:HEIQ)
Historical Stock Chart
From Dec 2023 to Dec 2024